Prostate-specific antigen: Does the current evidence support its use in prostate cancer screening?

Annals of Clinical Biochemistry

Volumn 48, Issue 4, 2011, Pages 310-316

  Duffy, Michael J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; FINASTERIDE; GLUTATHIONE TRANSFERASE P1; KALLIKREIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN;

ANXIETY; BRACHYTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; EJACULATION; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; INTESTINE FUNCTION; NEEDLE BIOPSY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; QUALITY OF LIFE; REVIEW; TRANSURETHRAL RESECTION; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

ANTIGENS, NEOPLASM; EARLY DETECTION OF CANCER; GREAT BRITAIN; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79960444176     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.010273     Document Type: Review

References (59)

1. Magklara A, Scorilas A, Stephan C, et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000;56:527-32
2. Lintula S, Stenman J, Bjartell A, et al. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005;63:324-9
3. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-83
4. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem 2008;54:1600-7
5. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
6. Mikolajczyk SD, Song Y, Wong JR, et al. Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 2004;37:519-28.
7. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894-904
8. Price CP, Allard J, Davies G, et al. Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 2001;38:188-216
9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
10. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61
11. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2031-6
12. Andriole GL, Levin DL, Crawford ED, et al. PLCO Project Team. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97:433-8
13. Holmström B, Johansson M, Bergh A, et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009;339:b3537
14. Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-44
15. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009 CA Cancer. J Clin 2009;59:225-49
16. Dubben HH. Trials of prostate-cancer screening are not worthwhile. Lancet Oncol 2009;10:294-8
17. Draisma G, Boer R, Otto SJ, et al.. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78
18. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9
19. Damber J-E, Aus G. Prostate cancer. Lancet 2008;371:1710-1721
20. Walsh PC, DeWeese TL, Eisenberger MA. Localised prostate cancer. N Engl J Med 2007;357:2696-705.
21. Bill-Axelson A, Holmberg L, Filén F, et al. Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54
22. Steineck G, Helgesen F, Adolfsson J, et al. Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6
23. Lane JA, Hamdy FC, Martin RM, et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010;46:3095-101
24. Djulbegovic M, Beyth R, Neuberger MN, et al. Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials. BMJ 2010;341:c4543
25. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310-9
26. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;26:1320-8
27. Roobol MJ, Kerkhof M, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for non-attendance and contamination in the European Randomized Study for Prostate Cancer (ERSPC). Eur Urol 2009;56:584-91
28. Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Scient World J 2010;10:1919-31.
29. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9:83-93. Review.
30. Reed AB, Parekh DJ. Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther 2010;10:103-14.
31. Stephan C, Jung K, Lein M, et al. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:1133-47.
32. Roddam AW, Duffy MJ, Hamdy FC, et al. NHS Prostate Cancer Risk Management Programme. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99
33. Lee R, Localio AR, Armstrong K, et al. Free PSA Study Group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006;67:762-8
34. Finne P, Auvinen A, Maattanen L, et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg per liter. Eur Urol 2008;54:362-70
35. Sturgeon CM, Duffy MJ, Stenman UK, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. Clin Chem 2008;54:e11-79
36. Semjonow A, Albrecht W, Bialk P, et al. Tumor markers in prostate cancer: EGTM recommendations. Anticancer Res 1999;19:2785-820
37. Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996;48:81-7
38. Schroder FH, Roobol MJ, van der Kwast TH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006;49:460-5
39. Carter HB, Ferucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Instit 2006;98:1521-27
40. Loeb S, Kettermann A, Ferrucci L, et al. The optimal application of prostate-specific antigen (PSA) velocity to predict high-risk disease. Eur Urol 2008;54:978-79
41. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591-7
42. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009;56:730-60
43. Soletormos G, Semjonow A, Sibley PE, et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005;51:1342-51
44. NCCN Practice Guidelines in Oncology, v.2.2010. Prostate Cancer Early Detection. See http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf (last checked 22 November 2010)
45. Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance and diagnostic accuracy. Clin Chim Acta 2008;389:1-6
46. Roobol MJ, Schröder FH, van Leenders GL, et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100). Eur Urol 2010 [Epub ahead of print]
47. Sokoll LJ, Wang Y, Feng Z, et al. [-2]proPSA for prostate cancer detection: an NCI Early Detection Research Network Validation Study. J Urol 2008;180:539-43
48. Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [22]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200
49. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79
50. Ulmert D, O'Brien MF, Bjartell AS, Lilja H. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009;6:384-91.
51. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ets transcription factor genes in prostate cancer. Science 2005;310:644-8
52. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcript and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8
53. Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69:714-20
54. Diamandis EP. Early prostate cancer antigen-2: a controversial prostate cancer biomarker? Clin Chem 2010;56:542-4
55. Phé V, Cussenot O, Rouprêt M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1364-70
56. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Int Med 2008;149:185-91
57. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232-41
58. Prostate Cancer Risk Management Programme. See http://www.cancerscreening.nhs.uk/prostate/index.html (last checked 12 November 2010)
59. Wolf AMD, Wender RC, Etzioni RE, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98